MMP2 as an independent prognostic stratifier in oral cavity cancers

References

• NCCN. https://www.nccn.org/professionals/physician_gls/default.aspx.
   Google Scholar
• Gañán L, López M, García J, Esteller E, Quer M, León X. Management of recurrent head and neck cancer: variables related to salvage surgery. Eur Arch Oto-Rhino-Laryngol Off J Eur Fed Oto-Rhino-Laryngol Soc EUFOS Affil Ger Soc Oto-Rhino-Laryngol - Head Neck Surg. 2016 Dec;273(12):4417–12.
   Google Scholar
• Argiris A, Karamouzis MV, Raben D, Ferris RL. Head and neck cancer. Lancet Lond Engl. 2008 May 17;371(9625):1695–1709. doi:10.1016/S0140-6736(08)60728-X.
   PubMed Web of Science ®Google Scholar
• Tam S, Araslanova R, Low T-H-H, Warner A, Yoo J, Fung K, MacNeil SD, Palma DA, Nichols AC. Estimating survival after salvage surgery for recurrent oral cavity cancer. JAMA Otolaryngol– Head Neck Surg. 2017 1;143(7):685–690. doi:10.1001/jamaoto.2017.0001.
   Google Scholar
• Ord RA, Kolokythas A, Reynolds MA. Surgical salvage for local and regional recurrence in oral cancer. J Oral Maxillofac Surg Off J Am Assoc Oral Maxillofac Surg. 2006 Sep;64(9):1409–1414. doi:10.1016/j.joms.2006.05.026.
   PubMed Web of Science ®Google Scholar
• Sacco AG, Cohen EE. Current treatment options for recurrent or metastatic head and neck squamous cell carcinoma. J Clin Oncol Off J Am Soc Clin Oncol. 2015 Oct 10;33(29):3305–3313. doi:10.1200/JCO.2015.62.0963.
   PubMed Web of Science ®Google Scholar
• Liao C-T, Chang JT-C, Wang H-M, Ng S-H, Hsueh C, Lee L-Y, Lin C-H, Chen I-H, Huang S-F, Cheng A-J. Salvage therapy in relapsed squamous cell carcinoma of the oral cavity: how and when? Cancer. 2008 Jan 1;112(1):94–103. doi:10.1002/cncr.23142.
   PubMed Web of Science ®Google Scholar
• Janot F, de Raucourt D, Benhamou E, Ferron C, Dolivet G, Bensadoun R-J, Hamoir M, Géry B, Julieron M, Castaing M, et al. Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma. J Clin Oncol Off J Am Soc Clin Oncol. 2008 Dec 1;26(34):5518–5523. doi:10.1200/JCO.2007.15.0102.
   PubMed Web of Science ®Google Scholar
• Zorat PL, Paccagnella A, Cavaniglia G, Loreggian L, Gava A, Mione CA, Boldrin F, Marchiori C, Lunghi F, Fede A, et al. Randomized phase III trial of neoadjuvant chemotherapy in head and neck cancer: 10-year follow-up. J Natl Cancer Inst. 2004 Nov 17;96(22):1714–1717. doi:10.1093/jnci/djh306.
   PubMed Web of Science ®Google Scholar
• Bossi P, Lo Vullo S, Guzzo M, Mariani L, Granata R, Orlandi E, Locati L, Scaramellini G, Fallai C, Licitra L, et al. Preoperative chemotherapy in advanced resectable OCSCC: long-term results of a randomized phase III trial. Ann Oncol Off J Eur Soc Med Oncol. 2014 Feb;25(2):462–466. doi:10.1093/annonc/mdt555.
   PubMed Web of Science ®Google Scholar
• Uppaluri R, Zolkind P, Lin T, Nussenbaum B, Jackson RS, Rich J. Neoadjuvant pembrolizumab in surgically resectable, locally advanced HPV negative head and neck squamous cell carcinoma (HNSCC). J Clin Oncol. 2017;35(suppl; abstr 6012). doi:10.1200/JCO.2017.35.15_suppl.6012.
   Google Scholar
• Ferris RL, Gonçalves A, Baxi S, Martens A, Gauthier H, Langenberg M, Spanos WC, Leidner RS, Kang H, Russell J. An open-label, multicohort, phase 1/2 study in patients with virus-associated cancers (checkmate 358): safety and efficacy of neoadjuvant nivolumab in squamous cell carcinoma of the head and neck. Annals of oncology. 2017;28(suppl_5): v605-v649. doi: 10.1093/annonc/mdx440
   Google Scholar
• Wise-Draper TM, Old MO, Worden FP, O’Brien PE, Cohen EEW, Dunlap N, Mierzwa ML, Casper K, Palackdharry S, Hinrichs B, et al. Phase II multi-site investigation of neoadjuvant pembrolizumab and adjuvant concurrent radiation and pembrolizumab with or without cisplatin in resected head and neck squamous cell carcinoma. J Clin Oncol. 2018;36(suppl; abstr 6017).
   Google Scholar
• Rivera C, Oliveira AK, Costa RAP, De Rossi T, Paes Leme AF. Prognostic biomarkers in oral squamous cell carcinoma: A systematic review. Oral Oncol. 2017;72:38–47. doi:10.1016/j.oraloncology.2017.07.003.
   PubMed Web of Science ®Google Scholar
• de Ruiter EJ, Ooft ML, Devriese LA, Willems SM. The prognostic role of tumor infiltrating T-lymphocytes in squamous cell carcinoma of the head and neck: A systematic review and meta-analysis. Oncoimmunology. 2017;6(11):e1356148. doi:10.1080/2162402X.2017.1356148.
   PubMed Web of Science ®Google Scholar
• Fridman WH, Zitvogel L, Sautès-Fridman C, Kroemer G. The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol. 2017 Dec;14(12):717–734. doi:10.1038/nrclinonc.2017.101.
   PubMed Web of Science ®Google Scholar
• Cristescu R, Mogg R, Ayers M, Albright A, Murphy E, Yearley J, Sher X, Liu XQ, Lu H, Nebozhyn M, et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science. 2018 12;362:6411. doi:10.1126/science.aar3593.
   Web of Science ®Google Scholar
• Gorbachev AV, Kobayashi H, Kudo D, Tannenbaum CS, Finke JH, Shu S, Farber JM, Fairchild RL. CXC chemokine ligand 9/monokine induced by IFN-gamma production by tumor cells is critical for T cell-mediated suppression of cutaneous tumors. J Immunol Baltim Md 1950. 2007 Feb 15;178(4):2278–2286.
   Google Scholar
• Zhang YJ, Rutledge BJ, Rollins BJ. Structure/activity analysis of human monocyte chemoattractant protein-1 (MCP-1) by mutagenesis. Identification of a mutated protein that inhibits MCP-1-mediated monocyte chemotaxis. J Biol Chem. 1994 Jun 3;269(22):15918–15924.
   PubMed Web of Science ®Google Scholar
• Van Damme J, Proost P, Lenaerts JP, Opdenakker G. Structural and functional identification of two human, tumor-derived monocyte chemotactic proteins (MCP-2 and MCP-3) belonging to the chemokine family. J Exp Med. 1992 Jul 1;176(1):59–65. doi:10.1084/jem.176.1.59.
   PubMed Web of Science ®Google Scholar
• Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 2010 Apr 2;141(1):52–67. doi:10.1016/j.cell.2010.03.015.
   PubMed Web of Science ®Google Scholar
• Gromov P, Gromova I, Olsen CJ, Timmermans-Wielenga V, Talman M-L, Serizawa RR, Moreira JMA. Tumor interstitial fluid - a treasure trove of cancer biomarkers. Biochim Biophys Acta. 2013 Nov;1834(11):2259–2270. doi:10.1016/j.bbapap.2013.01.013.
   PubMed Web of Science ®Google Scholar
• Li S-J, Peng M, Li H, Liu B-S, Wang C, Wu J-R, Li Y-X, Zeng R. Sys-BodyFluid: a systematical database for human body fluid proteome research. Nucleic Acids Res. 2009 Jan;37(Database issue):D907–912. doi:10.1093/nar/gkn849.
   PubMed Web of Science ®Google Scholar
• Stone MD, Odland RM, McGowan T, Onsongo G, Tang C, Rhodus NL, Jagtap P, Bandhakavi S, Griffin TJ. Novel in situ collection of tumor interstitial fluid from a head and neck squamous carcinoma reveals a unique proteome with diagnostic potential. Clin Proteomics. 2010 Sep;6(3):75–82. doi:10.1007/s12014-010-9050-3.
   PubMedGoogle Scholar
• Yang X, Chu Y, Wang Y, Zhang R, Xiong S. Targeted in vivo expression of IFN-gamma-inducible protein 10 induces specific antitumor activity. J Leukoc Biol. 2006 Dec;80(6):1434–1444. doi:10.1189/jlb.0306212.
   PubMed Web of Science ®Google Scholar
• Li J, Fu C, Speed TP, Wang W, Symmans WF. Accurate RNA sequencing from formalin-fixed cancer tissue to represent high-quality transcriptome from frozen tissue. JCO Precis Oncol. 2018:2, 1-9.
   Web of Science ®Google Scholar
• Chen C-H, Chien C-Y, Huang -C-C, Hwang C-F, Chuang H-C, Fang F-M, Huang H-Y, Chen C-M, Liu H-L, Huang C-Y. Expression of FLJ10540 is correlated with aggressiveness of oral cavity squamous cell carcinoma by stimulating cell migration and invasion through increased FOXM1 and MMP-2 activity. Oncogene. 2009 Jul 30;28(30):2723–2737. doi:10.1038/onc.2009.128.
   PubMed Web of Science ®Google Scholar
• Fan H-X, Li H-X, Chen D, Gao Z-X, Zheng J-H. Changes in the expression of MMP2, MMP9, and ColIV in stromal cells in oral squamous tongue cell carcinoma: relationships and prognostic implications. J Exp Clin Cancer Res CR. 2012 Oct 29;31:90. doi:10.1186/1756-9966-31-90.
   PubMed Web of Science ®Google Scholar
• Aparna M, Rao L, Kunhikatta V, Radhakrishnan R. The role of MMP-2 and MMP-9 as prognostic markers in the early stages of tongue squamous cell carcinoma. J Oral Pathol Med Off Publ Int Assoc Oral Pathol Am Acad Oral Pathol. 2015 May;44(5):345–352.
   Google Scholar
• Ruokolainen H, Pääkkö P, Turpeenniemi-Hujanen T. Tissue and circulating immunoreactive protein for MMP-2 and TIMP-2 in head and neck squamous cell carcinoma–tissue immunoreactivity predicts aggressive clinical course. Mod Pathol Off J U S Can Acad Pathol Inc. 2006 Feb;19(2):208–217.
   PubMed Web of Science ®Google Scholar
• Gunawardena I, Arendse M, Jameson MB, Plank LD, Gregor RT. Prognostic molecular markers in head and neck squamous cell carcinoma in a New Zealand population: matrix metalloproteinase-2 and sialyl Lewis x antigen. ANZ J Surg. 2015 Nov;85(11):843–848. doi:10.1111/ans.12424.
   PubMed Web of Science ®Google Scholar
• Gontarz M, Wyszyńska-Pawelec G, Zapała J, Czopek J, Lazar A, Tomaszewska R. Immunohistochemical predictors in squamous cell carcinoma of the tongue and floor of the mouth. Head Neck. 2016;38(Suppl 1):E747–753. doi:10.1002/hed.24087.
   PubMed Web of Science ®Google Scholar
• Katayama A, Bandoh N, Kishibe K, Takahara M, Ogino T, Nonaka S, Harabuchi Y. Expressions of matrix metalloproteinases in early-stage oral squamous cell carcinoma as predictive indicators for tumor metastases and prognosis. Clin Cancer Res Off J Am Assoc Cancer Res. 2004 Jan 15;10(2):634–640. doi:10.1158/1078-0432.CCR-0864-02.
   PubMed Web of Science ®Google Scholar
• Yokoyama K, Kamata N, Fujimoto R, Tsutsumi S, Tomonari M, Taki M, Hosokawa H, Nagayama M. Increased invasion and matrix metalloproteinase-2 expression by Snail-induced mesenchymal transition in squamous cell carcinomas. Int J Oncol. 2003 Apr;22(4):891–898.
   PubMed Web of Science ®Google Scholar
• Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E, Seiki M. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature. 1994 Jul 7;370(6484):61–65. doi:10.1038/370061a0.
   PubMed Web of Science ®Google Scholar
• Jobin PG, Butler GS, Overall CM. New intracellular activities of matrix metalloproteinases shine in the moonlight. Biochim Biophys Acta Mol Cell Res. 2017 Nov;1864(11Pt A):2043–2055. doi:10.1016/j.bbamcr.2017.05.013.
   PubMedGoogle Scholar
• Puram SV, Tirosh I, Parikh AS, Patel AP, Yizhak K, Gillespie S, Rodman C, Luo CL, Mroz EA, Emerick KS. Single-cell transcriptomic analysis of primary and metastatic tumor ecosystems in head and neck cancer. Cell. 2017 Dec 14;171(7):1611–1624.e24. doi:10.1016/j.cell.2017.10.044.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Liu R, Jin R, Fan Y, Li T, Shuai Y, Li X, Wang X, Luo J. Integrating clinical and genetic analysis of perineural invasion in head and neck squamous cell carcinoma. Front Oncol. 2019;9:434. doi:10.3389/fonc.2019.00434.
   PubMed Web of Science ®Google Scholar
• Massa ST, Cass LM, Osazuwa-Peters N, Christopher KM, Walker RJ, Varvares MA. Decreased cancer-independent life expectancy in the head and neck cancer population. Head Neck. 2017;39(9):1845–1853. doi:10.1002/hed.24850.
   PubMed Web of Science ®Google Scholar
• Gobin E, Bagwell K, Wagner J, Mysona D, Sandirasegarane S, Smith N, Bai S, Sharma A, Schleifer R, She J-X. A pan-cancer perspective of matrix metalloproteases (MMP) gene expression profile and their diagnostic/prognostic potential. BMC Cancer. 2019 Jun 14;19(1):581. doi:10.1186/s12885-019-5768-0.
   PubMedGoogle Scholar
• Zhong Y, Lu Y-T, Sun Y, Shi Z-H, Li N-G, Tang Y-P, Duan J-A. Recent opportunities in matrix metalloproteinase inhibitor drug design for cancer. Expert Opin Drug Discov. 2018;13(1):75–87. doi:10.1080/17460441.2018.1398732.
   PubMed Web of Science ®Google Scholar
• Scannevin RH, Alexander R, Haarlander TM, Burke SL, Singer M, Huo C, Zhang Y-M, Maguire D, Spurlino J, Deckman I. Discovery of a highly selective chemical inhibitor of matrix metalloproteinase-9 (MMP-9) that allosterically inhibits zymogen activation. J Biol Chem. 2017 27;292(43):17963–17974. doi:10.1074/jbc.M117.806075.
   PubMed Web of Science ®Google Scholar
• Van Tubergen EA, Banerjee R, Liu M, Vander Broek R, Light E, Kuo S, Feinberg SE, Willis AL, Wolf G, Carey T, et al. Inactivation or loss of TTP promotes invasion in head and neck cancer via transcript stabilization and secretion of MMP9, MMP2, and IL-6. Clin Cancer Res Off J Am Assoc Cancer Res. 2013 Mar 1;19(5):1169–1179. doi:10.1158/1078-0432.CCR-12-2927.
   PubMed Web of Science ®Google Scholar
• Jedryka M, Chrobak A, Chelmonska-Soyta A, Gawron D, Halbersztadt A, Wojnar A, Kornafel J. Matrix metalloproteinase (MMP)-2 and MMP-9 expression in tumor infiltrating CD3 lymphocytes from women with endometrial cancer. Int J Gynecol Cancer Off J Int Gynecol Cancer Soc. 2012 Oct;22(8):1303–1309. doi:10.1097/IGC.0b013e318269e27b.
   PubMed Web of Science ®Google Scholar
• Li H, Huang N, Zhu W, Wu J, Yang X, Teng W, Tian J, Fang Z, Luo Y, Chen M. Modulation the crosstalk between tumor-associated macrophages and non-small cell lung cancer to inhibit tumor migration and invasion by ginsenoside Rh2. BMC Cancer. 2018 May 22;18(1):579. doi:10.1186/s12885-018-4299-4.
   PubMedGoogle Scholar
• Espinoza-Sánchez NA, Chimal-Ramírez GK, Mantilla A, Fuentes-Pananá EM. IL-1β, IL-8, and matrix metalloproteinases-1, −2, and −10 are enriched upon monocyte-breast cancer cell cocultivation in a matrigel-based three-dimensional system. Front Immunol. 2017;8:205.
   PubMed Web of Science ®Google Scholar
• Cardoso AP, Pinto ML, Pinto AT, Pinto MT, Monteiro C, Oliveira MI, Santos SG, Relvas JB, Seruca R, Mantovani A, et al. Matrix metalloproteases as maestros for the dual role of LPS- and IL-10-stimulated macrophages in cancer cell behaviour. BMC Cancer. 2015 Jun 5;15(1):456. doi:10.1186/s12885-015-1466-8.
   PubMedGoogle Scholar
• Godefroy E, Manches O, Dréno B, Hochman T, Rolnitzky L, Labarrière N, Guilloux Y, Goldberg J, Jotereau F, Bhardwaj N, et al. Matrix metalloproteinase-2 conditions human dendritic cells to prime inflammatory T(H)2 cells via an IL-12- and OX40L-dependent pathway. Cancer Cell. 2011 Mar 8;19(3):333–346. doi:10.1016/j.ccr.2011.01.037.
   PubMed Web of Science ®Google Scholar
• Lee B-K, Kim M-J, Jang H-S, Lee H-R, Ahn K-M, Lee J-H, Choung PH, Kim MJ. A high concentration of MMP-2/gelatinase A and MMP-9/gelatinase B reduce NK cell-mediated cytotoxicity against an oral squamous cell carcinoma cell line. Vivo Athens Greece. 2008 Oct;22(5):593–597.
   PubMed Web of Science ®Google Scholar
• McQuibban GA, Gong J-H, Wong JP, Wallace JL, Clark-Lewis I, Overall CM. Matrix metalloproteinase processing of monocyte chemoattractant proteins generates CC chemokine receptor antagonists with anti-inflammatory properties in vivo. Blood. 2002 Aug 15;100(4):1160–1167. doi:10.1182/blood.V100.4.1160.h81602001160_1160_1167.
   PubMed Web of Science ®Google Scholar
• Goetzl EJ, Banda MJ, Leppert D. Matrix metalloproteinases in immunity. J Immunol Baltim Md 1950. 1996 Jan 1;156(1):1–4.
   Google Scholar
• Godefroy E, Moreau-Aubry A, Diez E, Dreno B, Jotereau F, Guilloux Y. alpha v beta3-dependent cross-presentation of matrix metalloproteinase-2 by melanoma cells gives rise to a new tumor antigen. J Exp Med. 2005 Jul 4;202(1):61–72. doi:10.1084/jem.20042138.
   PubMed Web of Science ®Google Scholar
• Amin MB, Edge S, Greene F, Byrd DR, Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR, Sullivan DC, et al. AJCC cancer staging manual. 8th. New York, NY, USA; Springer; 2017.
   Google Scholar
• Agra IMG, Carvalho AL, Ulbrich FS, de Campos OD, Martins EP, Magrin J, Kowalski LP. Prognostic factors in salvage surgery for recurrent oral and oropharyngeal cancer. Head Neck. 2006 Feb;28(2):107–113. doi:10.1002/hed.20309.
   PubMed Web of Science ®Google Scholar
• Hoffmann C, Noel F, Grandclaudon M, Michea P, Surun A, Faucheux L, Philemon Sirven P, Lantz O, Rochefort J, Klijanienko J. PDL1 and ICOSL discriminate human secretory and helper dendritic cells. bioRxiv [Internet]. 2019 Aug 1 [cited 2019 Aug 2]. doi:10.1101/721563
   Google Scholar